ImmunoPrecise (IPA) - Gross Profit Rate

Corporate emblem and logo of ImmunoPrecise Antibodies (IPA)

The development of ImmunoPrecise Antibodies (IPA) has been driven by the implementation of autonomous microfluidic systems for B-cell screening. Gross margin after deducting cost of sales demonstrates current dynamics, where the 47.20 metric confirms the current level of efficiency. Looking ahead, success depends on the commercial return of the AI platform and the resilience of biopharma orders to interest rate fluctuations, which will determine the long-term valuation of the business.

ImmunoPrecise Antibodies (IPA) Gross Profitability: for the period 07/04/2022 - 09/04/2025

Financial and market metric breakdowns for ImmunoPrecise Antibodies (IPA)

- stock value and consensus price forecast:
Fundamental valuation:immunoprecise.com, IPA
Flagship merchandise of ImmunoPrecise

The B2B model of ImmunoPrecise Antibodies (IPA), based on providing biotechnological platforms to pharma behemoths, determines the company's direct cost structure. By analyzing the gross margin, an investor can see the portion of revenue net of production costs, which reflects the efficiency of resource management. The trend in this gross margin metric allows for an assessment of the balance between the high pricing power of intellectual services and capital expenditures in product development.

Main competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|RNAZ - Return on Gross Profit|BNGO: Return on Gross Profit|APDN (Applied DNA Sciences Inc) - Gross Return on Sales|BLUE (Bluebird Bio) - Return on Gross Profit|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability